Nowadays clinical therapy witnesses a challenging bacterial resistance limiting the available armament of antibiotics. Over decades strains resistant to all antibiotics have been selected while medicinal chemists were not able to develop agents capable of destroying them or to prevent their extension. In particular, carbapenem-resistant Enterobacteriaceae (CRE), representing one of the most common human pathogens, have been reported with increased frequency since their first identification twenty years ago. The enterobacterial carbapenemases differ from the extended spectrum β-lactamases (ESBL) in their ability to hydrolyze β-lactams, cephalosporins and most importantly the last resort monobactams and carbapenems. They are progressively spreading throughout the world therefore leaving no effective β-lactam to cure bacterial infections. Several BL-carbapenemase X-ray structures have been determined making these enzymes attractive targets for structure-based drug design studies. However very little has been done so far to powerfully address the inhibitor design issues for this emerging type of BL. Here we focus on the structural basis for molecular recognition and for broad spectrum activity of class A carbapenemases: based on available 3-dimensional structural information we identify a theoretical pharmacophoric model as a starting point for the development of needed carbapenemases inhibitors. Targetable "hot spots" on the enzyme-binding site were identified using a computational approach.
|Data di pubblicazione:||2015|
|Titolo:||Decoding the structural basis for carbapenem hydrolysis by class A β- lactamases: fishing for a pharmacophore|
|Autori:||Tondi, Donatella; Cross, Simon; Venturelli, Alberto; Costi, Maria Paola; Cruciani, Gabriele; Spyrakis, Francesca|
|Appare nelle tipologie:||Articolo su rivista|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris